NCT00871338View on ClinicalTrials.gov

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

June 24, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

December 9, 2010

Conditions
Neisseria MeningitidisHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

GSK2197870A

3 doses given at 2, 3 and 4 months of age

BIOLOGICAL

Prevenar™

3 co-administered doses, intramuscular into right thigh

BIOLOGICAL

Menitorix™

1 booster dose at 12 months of age

BIOLOGICAL

Pediacel™

3 doses given at 2, 3 and 4 months of age

BIOLOGICAL

Menjugate™

2 doses given at 3 and 4 months of age

Trial Locations (5)

CB7 4HF

GSK Investigational Site, Ely

SO16 6YD

GSK Investigational Site, Southampton

OX3 7LJ

GSK Investigational Site, Oxford

BS2 8AE

GSK Investigational Site, Bristol

SW17 0QT

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY